Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight (ENLIGHTEN-4)
A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4)
Sponsor: Eli Lilly and Company
A observational or N/A phase clinical study on Osteoarthritis and Overweight or Obesity, this trial is actively recruiting participants. The trial is conducted by Eli Lilly and Company and has accumulated 2 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
2 versions recorded-
Apr 18, 2026 — Present [daily]
Recruiting
Phase: PHASE3 → None
-
Feb 2026 — Apr 2026 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beaver, United States , Beijing, China , Bellaire, United States , Bengbu, China , Bochum, Germany , Bristol, United Kingdom , Brno, Czechia , Brno, Czechia , Brooklyn, United States , Buenos Aires, Argentina and 144 more locations